PCSKS9 inhibitors work to reduce artery-clogging cholesterol by almost twice as much as the older drugs. However, the high price of them is alarming. Due to the high prices this once highly praised solution is having a hard being sold.
Written by Matthew Perrone, 4/20/16, The Seattle Times
Read our previous blog post about the introduction of PCSKS9 Inhibitors.
In a recent article in the Bristol Herald Courier, David Balto gives a great summary of the problems with the pharmacy benefit management industry, such
In a recent article at BenefitsPRO, Dan Cook talks about the movement to have employers “rise up and fight their own battles with the drug
“Today, one in four Americans who need prescription drugs struggle to afford them — one in four,” president Joe Biden. The last two administrations have
